uniQure N.V.

NASDAQ:QURE   3:59:58 PM EDT
29.71
+1.48 (+5.24%)
Products, Regulatory

uniQure Enrolls First Two Patients in Second Cohort of Trial of AMT-130 for Treatment of Huntington’s Disease

Published: 06/16/2021 11:49 GMT
uniQure N.V. (QURE) - Uniqure Announces Enrollment of First Two Patients in Second Cohort of Phase I/ii Clinical Trial of Amt-130 for the Treatment of Huntington’s Disease.
Uniqure - Look Forward to Ongoing Patient Enrollment in Second Cohort & to Initiating Clinical Development of Amt-130 in Europe in H2 of This Year.
Uniqure NV - Remain on Track to Share Initial Imaging and Biomarker Data From U.S. Clinical Trial Before End of Year.